The Danish drugmaker Novo Nordisk said it has invested $6.5 billion this year ... markets a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy. Shares of Hims & Hers ...
On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
Demand GLP-1 Medications as Prescription Drug Market GrowsSchaumburg, Illinois, Feb 21, 2025 - (ACN Newswire) - Giftify, Inc.
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...
Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.
The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs as supply conditions for the GLP-1s improve after an ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results